Talk:Cabergoline

This article is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

Summary sheet: Cabergoline

Chemical Nomenclature

Common names

Cabergoline, Dostinex

Systematic name

(6aR,9R,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide

Class Membership

Psychoactive class

Psychedelic

Chemical class

Lysergamide

Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions

Cabergoline is a chemical of the lysergamide and ergopeptine classes. It is a close derivative of LSD, more specifically, AL-LAD, but instead shares many effects with related, non-psychedelic medicinal compounds such as ergotamine, ergonovine or lisuride. It is occasionally prescribed to treat symptoms of high prolactin levels and managing Parkinson's disease.

Cabergoline is not predominantly psychedelic, it mainly exerts its effects at the dopamine D₂ receptor as an agonist but has comparatively little effect on the serotonin 5-HT_2A receptor where it acts as a partial agonist.

Cabergoline has little recreational value other than its unique property of reducing or eliminating the male refractory period, allowing men to experience multiple ejaculatory orgasms in rapid succession.^[1]^[2]

External links

References

↑ Krüger, T. H. C., Haake, P., Haverkamp, J., Krämer, M., Exton, M. S., Saller, B., Leygraf, N., Hartmann, U., Schedlowski, M. (December 2003). "Effects of acute prolactin manipulation on sexual drive and function in males". The Journal of Endocrinology. 179 (3): 357–365. doi:10.1677/joe.0.1790357. ISSN 0022-0795.
↑ Hollander, A. B., Pastuszak, A. W., Hsieh, T.-C., Johnson, W. G., Scovell, J. M., Mai, C. K., Lipshultz, L. I. (March 2016). "Cabergoline in the Treatment of Male Orgasmic Disorder-A Retrospective Pilot Analysis". Sexual Medicine. 4 (1): e28–33. doi:10.1016/j.esxm.2015.09.001. ISSN 2050-1161.

[1] Krüger, T. H. C., Haake, P., Haverkamp, J., Krämer, M., Exton, M. S., Saller, B., Leygraf, N., Hartmann, U., Schedlowski, M. (December 2003). "Effects of acute prolactin manipulation on sexual drive and function in males". The Journal of Endocrinology. 179 (3): 357–365. doi:10.1677/joe.0.1790357. ISSN 0022-0795.

[2] Hollander, A. B., Pastuszak, A. W., Hsieh, T.-C., Johnson, W. G., Scovell, J. M., Mai, C. K., Lipshultz, L. I. (March 2016). "Cabergoline in the Treatment of Male Orgasmic Disorder-A Retrospective Pilot Analysis". Sexual Medicine. 4 (1): e28–33. doi:10.1016/j.esxm.2015.09.001. ISSN 2050-1161.

[1]

[2]

Talk:Cabergoline

See also

External links

References

Navigation menu

Search

Yolo